Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 816-821

  Garnier, Jean Pierre ^a,b   Letellier, Sabine ^a,b   Cassinat, Bruno ^b   Lebbé, Celeste ^b   Kerob, Delphine ^b   Baccard, Michel ^b   Morel, Patrice ^b   Basset Seguin, Nicole ^b   Dubertret, Louis ^b   Bousquet, Bernard ^a,b   Stoitchkov, Konstantin ^c,d   Bricon, Thierry Le ^b  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c National Oncology Center Bulgaria   (Bulgaria)

^d EORTC DATA CENTER   (Belgium)

Author keywords

Melanoma; Metastasis; Prognosis; Tumour marker

Indexed keywords

LACTATE DEHYDROGENASE; LEVODOPA; MELANOMA INHIBITORY ACTIVITY PROTEIN; MONOPHENOL MONOOXYGENASE; PROTEIN; PROTEIN S100B; TUMOR MARKER; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; FEMALE; HUMANS; LEVODOPA; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 33947654470     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.11.022     Document Type: Article

References (25)

1. Brochez L., and Naeyaert J.M. Serological markers for melanoma. Br J Dermatol 143 (2000) 256-268
2. Le Bricon T., Stoitchkov K., Letellier S., et al. Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma. Clin Chim Acta 282 (1999) 101-113
3. Von Schoultz E., Hansson L.O., Djureen E., et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6 (1996) 133-137
4. Buer J., Probst M., Franzke A., et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 75 (1997) 1373-1376
5. Hauschild A., Engel G., Brenner W., et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140 (1999) 1065-1071
6. Matsushita Y., Hatta N., Wakamatsu K., et al. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Melanoma Res 12 (2002) 319-323
7. Deichmann M., Benner A., Bock M., et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17 (1999) 1891-1896
8. Garbe C., Leiter U., Ellwanger U., et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97 (2003) 1737-1745
9. Letellier S., Garnier J.P., Spy J., et al. Development of metastases in malignant melanoma is associated with an increase of plasma L-DOPA/tyrosine ratio. Melanoma Res 9 (1999) 389-394
10. Wimmer I., Meyer J., Seifert B., et al. Prognostic value of serum 5-S-Cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57 (1997) 5073-5076
11. Ross-Bullon M.R., Sanchez-Pedreno P., and Martinez-Liarte J.H. Serum tyrosine hydroxylase activity is increased in melanoma patients. A ROC curve analysis. Cancer Lett 129 (1998) 151-155
12. Stoitchkov K., Letellier S., Garnier J.P., et al. Evaluation of the serum L-DOPA/tyrosine ratio as a melanoma marker. Melanoma Res 13 (2003) 287-293
13. Letellier S., Garnier J.P., Spy J., and Bousquet B. Determination of the L-DOPA/tyrosine ratio in human plasma by high performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma. J Chromatography B 696 (1997) 9-17
14. Stoitchkov K., Letellier S., Garnier J.-P., et al. Melanoma progression and serum L-DOPA/tyrosine ratio: a comparison with S100B. Melanoma Res 12 (2002) 255-262
15. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for staging of cancer, 4th ed. Philadelphia, P.A.: J.B.Lippincott, 1995, 1555-60.
16. Kim C.J.U., Reintgen D.S., and Balch C.M. The new melanoma staging system. Cancer Control 9 (2002) 9-15
17. Negrier S., Fervers B., Bailly C., et al. Standards, options et recommandations pour la prise en charge des patients atteints de mélanome cutané. Presse Med 29 (2000) 1317-1326
18. Bosserhoff A.K., Kuster H., and Hein R. Elevated MIA levels in the serum of pregnant women and of children. Clin Exp Dermatol 29 (2004) 628-629
19. Persson L., Hardemark H.G., Gustavsson J., et al. S100-protein and neurone-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18 (1987) 911-918
20. Wagner V., Rudi J., Naher H., and Stremmel W. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Med Oncol 17 (2000) 35-38
21. Riley P. Mechanistic aspects of the control of tyrosinase activity. Pigment Cell Res 6 (1993) 182-185
22. Ghanem G., Loir B., Morandini R., et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 94 (2001) 586-590
23. Schultz E.S., Diepgen T.L., and Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138 (1998) 426-430
24. Hansson L.O., Von Schoultz E., Djureen E., et al. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res 17 (1997) 3971-3974
25. Bonfrer J.M.G., Korse C.M., Nieweg O.E., and Rankin E.M. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77 (1998) 2210-2214